RECURRENT ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA
Clinical trials for RECURRENT ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Cancer-Fighting virus trial seeks to target tumors
Disease control OngoingThis early-stage trial is testing a modified virus designed to infect and kill cancer cells in patients with advanced or recurrent endometrial cancer. The main goal is to find a safe dose and understand the side effects. Some patients also receive an additional oral drug that may…
Matched conditions: RECURRENT ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Apr 04, 2026 03:51 UTC
-
New drug combo trial aims to slow advanced uterine cancer
Disease control OngoingThis study is testing whether adding a new drug called ipatasertib to an existing hormone therapy (megestrol acetate) is more effective at controlling advanced endometrial cancer that has returned or spread. The trial will first find the safest dose of the combination, then compa…
Matched conditions: RECURRENT ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 04, 2026 03:50 UTC
-
New drug cocktail tested in battle against recurrent uterine cancer
Disease control OngoingThis study is testing whether adding a drug called ribociclib to a two-drug combination (everolimus and letrozole) works better to control advanced or recurrent endometrial cancer. It involves about 90 patients whose cancer has spread or returned. The goal is to see if the three-…
Matched conditions: RECURRENT ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
New pill tested to fight returning gynecologic cancers
Disease control OngoingThis study is testing an oral medication called tazemetostat for people whose ovarian or endometrial cancer has returned after previous treatments. The drug aims to stop cancer cell growth and shrink tumors. Researchers are enrolling 62 patients to see how well the treatment work…
Matched conditions: RECURRENT ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
Major trial tests new weapon against advanced uterine cancer
Disease control OngoingThis large, late-stage study is testing whether adding an immunotherapy drug called pembrolizumab to standard chemotherapy works better for treating advanced or recurrent endometrial cancer. It involves over 800 patients with stage III, IV, or returning cancer. The goal is to see…
Matched conditions: RECURRENT ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 25, 2026 14:09 UTC